[ad_1]
The trial of the third phase of the Oxford University corona vaccine has been postponed, but the vaccine is expected to hit the market later this year, according to AstraZeneca.
“We could get the vaccine at the end of this year or early next year,” said Pascal Soriot, chief executive officer (CEO) of the multinational pharmaceutical company. That possibility still exists.
The AstraZeneca and Oxford trials were postponed last Wednesday when a UK woman fell ill and was hospitalized with a test vaccine. However, AstraZeneca says that getting sick and putting off rehearsal is part of their normal routine.
AstraZeneca’s ‘AZD1222’ vaccine is one of nine currently being tested in the third phase by human application. The company is testing the vaccine in 32 cities in the United States, including 30,000 people in Brazil and several countries in South America.
Meanwhile, after the trial was postponed, Oxford University and AstraZeneca began examining security issues. Pascal Soriot, CEO of AstraZeneca, says the woman was hospitalized with back pain. She suffered from severe nervous symptoms. However, he was discharged from the hospital last Wednesday after treatment. Surrey said this in a private conference call with JP Morgan, the bank that invests in the vaccine.
The trial was also postponed in July because one of the participants had nervous symptoms, Pascal Soriot said. However, after the test, it was found that he did not get sick from the vaccination.
Francis Sellers Collins, director of the US National Institutes of Health, told the US Senate after the trial was postponed that the illness of one or two people in such a large trial did not question safety. and vaccine efficacy. Anyone can get sick at trial. The cause of the disease may not be a vaccine. The correct information will be provided by searching.
[ad_2]
